FDA Approves Aripiprazole for Treatment of Bipolar I Maintenance

May 2, 2005 FDA Approves Aripiprazole for Treatment of Bipolar I Maintenance  On March 7, 2005, the Food and Drug Administration (FDA) approved Aripiprazole, (marketed as Ambilify by Bristol-Myers Squibb Company) an atypical antipsychotic, for the maintenance treatment of bipolar I disorder. The drug was approved for maintaining efficacy in patients with bipolar I who have experienced a recent manic or mixed episode and have been stabilized for at least six consecutive weeks.  The FDA first approved Aripiprazole on September 29, 2004, for the treatment of acute bipolar mania, including manic and mixed episodes associated with the condition. The . . .